9 results about "Interferon therapy" patented technology

Providing a CDKN2a companion diagnostic for interferon therapy for bladder cancer. [Solution] A method for treating bladder cancer, comprising the steps of: diagnosing bladder cancer in a human; measuring the CDKN2A expression level in the human; and subsequently injecting an interferon expression-inducing agent into the human. Non-muscle-invasive bladder cancer (NMIBC) represents the most common disease state in patients with newly diagnosed bladder cancer. Those with high-grade (HG) tumors are at significant risk of both recurrence and progression.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

Methods of treating a hepatitis delta virus (HDV) infection in a human patient are provided. In some embodiments, the method comprising administering to the patient a therapeutically effective amount of interferon lambda for at least four weeks.

The present application relates to the technical field of new antiviral drug active ingredients, and particularly relates to application of a small-molecule compound inhibitor of lactate dehydrogenase A in preparation of an antiviral drug, wherein the inhibitor is Kinetin or L67, which can be directly combined with lactate dehydrogenase A (LDHA), on one hand, significantly reduces the expression level of LDHA, reduces the negative regulation of LDHA to the IFN-I channel from the source; on the other hand, can specifically destroy the LDHA / STAT2 / HDAC3 ternary complex induced by IFN-I, antagonize the transcriptional regulation function of LDHA, and release the inhibition of the antiviral effect of IFN-I. The present application can solve the core pain point that the response rate of IFN-alpha in the treatment of chronic hepatitis B (CHB), influenza virus or new coronavirus and other viral infection diseases is not high in clinic; through the combined scheme of Kinetin / L67+IFN-I, the response efficiency of clinical interferon treatment is improved.

The invention generally relates to the field of diagnostics and prognostics. In particular, the invention relates to a method for determining the responsiveness of a chronic hepatitis B (CHB) patient to IFN-alpha treatment. In an aspect of the invention, there is provided a method for determining the responsiveness of a chronic hepatitis B (CHB) patient to IFN-alpha treatment, comprising: (a) measuring an expression level of at least one biomarker of a prognostic biomarker panel selected from the group consisting of NQO2, MBL2, IGKV3D-20, PKHD1L1, PGLYRP1, KHSRP, LCN2, and ROBO1 in a biological sample obtained from the patient, and (b) comparing the expression level of the at least one biomarker to corresponding expression level of a known non-responder, wherein an expression level higher than the corresponding expression level is indicative of a likelihood of a positive response to IFN-alpha treatment.

The invention discloses an interferon a4 prodrug with tumor microenvironment response and application of the interferon a4 prodrug, and belongs to the technical field of biological medicine. The amino acid sequence of the interferon a4 prodrug is as shown in SEQ ID NO. 2. The activity of the interferon a4 prodrug is masked through the MMP14 Linker and the PD-1 single-chain antibody responding to the tumor microenvironment, and the treatment toxicity of the interferon a4 can be reduced; after the tumor microenvironment response Linker is broken by the MMP14 enzyme, a PD-1 single-chain antibody is released, and the combination of PD-L1 and PD-1 is effectively blocked, so that the immunosuppression is reversed, and a multifunctional synergistic effect is realized; besides, the Fc segment sequence fused at the C terminal of the IFNa4 can improve the stability and the half-life period of the interferon a4 prodrug, the anti-tumor effect is effectively enhanced, and a good clinical application prospect is shown.

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and / or preventing postoperative tumor recurrence and / or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and / or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

Compositions, kits, systems, and methods for reducing viability of cancer cells and treating cancer, as well as reducing a volume of a tumor and / or preventing an increase in volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating electric field in combination with administration of at least one composition comprising interferon gamma.